Cross-border Life Sciences Transactions: June 2021 Summary

Cross-border Life Sciences Transactions: June 2021 Summary

Transactions: Licensing, Investment, and Partnerships Photo by Antonella Vilardo on Unsplash Cinda Biopharmaceuticals enters ADC On June 29, Cinda announced the signing of a non-exclusive, target-specific licensing agreement with Synaffix B.V. Synaffix will provide...
STAR Market Celebrates its Second Anniversary

STAR Market Celebrates its Second Anniversary

The Shanghai Stock Exchange and Technology Innovation Board (STAR Market) recently celebrated its second anniversary. The past two years have been busy ones. As of June 2, 2021, a total of 517 companies had applied for registration with STAR Market, of which 314 were...
Future trends in robotic surgery: remote and AI

Future trends in robotic surgery: remote and AI

The presence of robotic surgery has brought a lot of change to the OR. Compared with traditional surgery methods, robotic surgery can have such advantages as being less invasive and having higher precision, less blood, less scarring, reduced infection rates, and a...
Industrial Park Insights | Taicang Biomedical Industrial Park

Industrial Park Insights | Taicang Biomedical Industrial Park

On November 27, 2020, at a signing ceremony in Shaxi, MyBioGate, Jiangsu Industrial Technology Research Institute, Taicang Innovation Investment Development, and Taicang Biomedical Industrial Park officially signed a contract to form the joint venture company TomoWave...
Overview of global pharmaceutical transactions in April

Overview of global pharmaceutical transactions in April

According to research from MyBioGate, in April, the global pharmaceutical industry reached at least 23 transactions, mainly mergers and acquisitions and licensing. M&A transactions mainly occurred between non-Chinese pharmaceutical companies. Two M&As were...
Largest Biomedical IPO of 2020: RemeGen

Largest Biomedical IPO of 2020: RemeGen

New drug approval: Telitacicept On March 12, the State Food and Drug Administration in China issued an announcement, authorizing conditional approval for RemeGen’s therapeutic biological product for injection, Telitacicept. The drug is an innovative drug TACl-Fc...

Analysis of Fourth-Generation EGFR Inhibitors

EGFR-TKI Lung cancer contributes to the highest number of new and fatal cases of malignant tumors in the world with regards to cancer cases. About 85% of lung cancer cases are non-small cell lung cancer (NSCLC). Most patients with NSCLC often have mutations that lead...
How will new dual-acting drugs affect the ADHD market?

How will new dual-acting drugs affect the ADHD market?

Author: HE Sheng Attention deficit hyperactivity disorder (ADHD) is one of the most common mental disorders affecting children. Guidelines within the American Psychiatric Association’s Diagnostic and Statistical Manual, Fifth edition (DSM-5) are used to diagnose ADHD....
Join us now for the MyBioGate global BD&FA partners

Join us now for the MyBioGate global BD&FA partners

MyBioGate is committed to connecting global healthcare innovations with Chinese resources. To bring our business into the next stage, we are now recruiting business development and finance adviser partner worldwide. We expect part-time employees to help us develop...
Join us now for the MyBioGate global BD&FA partners

Top-tier Chinese Pharmaceutical company profile: BeiGene

BeiGene Co., Ltd   2019 Revenue: US$ 428.21 million Number of Employees: 4,200+ Founded: 2010 Overview BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to...
Exclusive Interview with Genetron Health’s CEO Sizhen Wang

Exclusive Interview with Genetron Health’s CEO Sizhen Wang

“Give us a few more years and Genetron Health will be a leading precision medicine company, based in China but serving the world. This is our goal, ” Genetron Health CEO Sizhen Wang said in an interview with MyBioGate. One day prior to the interview, the...